INTRODUCTION OF THE PROSTATE CANCER RESEARCH AND PREVENTION ACT REAUTHORIZATION -- (Extensions of Remarks - June 17, 2005)
HON. FRANK A. LoBIONDO
OF NEW JERSEY
IN THE HOUSE OF REPRESENTATIVES
THURSDAY, JUNE 16, 2005
Mr. LOBIONDO. Mr. Speaker, I rise here today in support of the "Prostate Cancer Research and Prevention Act." This important piece of legislation will reauthorize through 2010 important programs at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) which will help increase awareness and surveillance of prostate cancer, address the serious issues of prostate cancer screening, and help unlock the mysteries of prostate cancer through research.
Prostate cancer is the second most common type of cancer found in American men. The American Cancer Society estimates that there will be about 232,090 new cases of prostate cancer in the United States in 2005 and that approximately 30,350 men will die of this disease. It is the second leading cause of cancer death in men, behind only lung cancer.
While these statistics remain alarming, the death rate for prostate cancer is actually decreasing in all racial and ethnic groups. While 1 man in 6 will still be diagnosed with prostate cancer during his lifetime, only 1 man in 33 will now die of this disease. More men, especially African-American men and others in high risk categories, are being made aware of the risk of prostate cancer and being encouraged to take steps to ensure early detection.
This awareness and action is critically important when dealing with all cancers, but especially cancer of the prostate-which grows slowly and without symptoms and is all too often undetected until in its most advanced and incurable stage. That is why reauthorizing the "Prostate Cancer Research and Prevention Act" is so important.
Reauthorizing the "Prostate Cancer Research and Prevention Act" will allow the CDC to continue to comprehensively evaluate the effectiveness of various screening strategies for prostate cancer and to further expand public information and education programs about the issues regarding the disease. It will also allow the CDC to continue to make grants to States and local health departments to ensure that this information is being thoroughly spread, especially among communities and groups where the risk is highest. The bill also extends the authority of the National Cancer Institute at the NIH to conduct and support basic and clinical research to expand the understanding of the cause of prostate cancer and to ultimately find a cure for the disease. Reauthorizing these important programs will help continue the rising trend towards awareness and action and hopefully result in even fewer untimely deaths.
The American Cancer Society, the Men's Health Network and the Dean and Betty Gallo Prostate Cancer Center at the Cancer Institute of New Jersey join me in supporting this reauthorization of the "Prostate Cancer Research and Prevention Act." These organizations know first hand the important roles education, awareness and research play, and I applaud each of them for their dedication to battling this disease.
As National Men's Health Week draws to a close and we prepare to celebrate Father's Day on Sunday, I encourage each of you to reflect on the serious health threat that prostate cancer continues to pose for men across the country-including the men closest and most important to each of us, and urge my colleagues in the House to support the "Prostate Cancer Research and Prevention Act."